Fannie Mae, Freddie Mac shares tumble after conservatorship comments
BOTHELL, WA—Troy Wichterman, Chief Financial Officer of BioLife Solutions Inc. (NASDAQ:BLFS), a $1 billion market cap company with strong financial health according to InvestingPro metrics, sold 932 shares of the company’s common stock on April 9, 2025. The shares were sold at a price of $20.11 each, amounting to a total transaction value of $18,742. The stock currently trades at $21.88, up from the transaction price. Following this sale, Wichterman retains ownership of 188,310 shares. The company maintains a healthy current ratio of 4.54, indicating strong liquidity.
The sale was executed under a Rule 10b5-1 trading plan, which allows corporate insiders to set up a predetermined plan to sell company stock for purposes such as tax withholding obligations. For comprehensive insider trading analysis and additional insights, access the detailed Pro Research Report available on InvestingPro.
In other recent news, BioLife Solutions announced its financial results for the fourth quarter and the full year of 2024, reporting a total revenue of $22.7 million for the fourth quarter, which surpassed analyst estimates. The company posted a net loss of $2.0 million, which was smaller than anticipated. For the entire year, BioLife Solutions reported total revenue of $82.3 million, excluding discontinued operations. The Cell Processing segment, a key driver of growth, experienced a 31% year-over-year increase in revenue for the fourth quarter, marking its fifth consecutive quarter of growth.
Looking forward to 2025, BioLife Solutions anticipates total revenue growth of 16-20%, with the Cell Processing segment expected to grow 18-21%. Analyst firms such as H.C. Wainwright and Benchmark have responded positively to these results, with H.C. Wainwright raising the price target to $30 while maintaining a "Buy" rating. Benchmark also reiterated a "Buy" rating with a $30 target, citing the company’s positive earnings forecasts.
Additionally, KeyBanc Capital Markets maintained an Overweight rating on BioLife Solutions, highlighting the company’s strong market position and recent strategic moves. The firm expressed confidence in BioLife’s ability to expand its revenue through its Sexton portfolio and new product introductions. BioLife’s focus on its core biopreservation media business and the recent divestiture of non-core assets underscore its strategy to improve gross margins and achieve long-term growth targets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.